Literature DB >> 3418516

Influence of ligand choice on the apparent binding profile of gallamine to cardiac muscarinic receptors. Identification of three main types of gallamine-muscarinic receptor interactions.

N H Lee1, E E el-Fakahany.   

Abstract

The binding profile of the positively charged muscarinic antagonist, gallamine, was studied in rat heart homogenates. A proportion of the binding sites labeled by the tertiary muscarinic ligands [( 3H]quinuclidinyl benzilate (QNB) and [3H]atropine) were inaccessible to their quaternary analogs [( 3H]N-methyl-QNB (NMeQNB) and [3H]-N-methylscopolamine (NMS)] or gallamine. Whereas gallamine displaced the binding of [3H]NMeQNB with high affinity, biphasic competition curves were observed using [3H]NMS only at higher ligand concentrations. The rank order of potency of gallamine in allosterically decelerating ligand dissociation kinetics was: [3H]NMS greater than [3H]atropine greater than [3H]NMeQNB greater than [3H]QNB. Our calculations demonstrate that the displayed heterogeneity of gallamine binding sites detected using [3H]NMS, but not the tertiary ligands, might be accounted for by the allosteric modification of the binding of this ligand by gallamine. Based on these findings, the exhibited binding profile of gallamine to muscarinic receptors is influenced strongly by ligand choice, and also by the ligand concentration used in the binding experiment. Furthermore, it is concluded that gallamine binds to three major sites on the muscarinic receptor, thereby revealing an apparent heterogeneity of its binding sites, even in a tissue which presumably possesses one major muscarinic receptor subtype such as the heart. According to several lines of evidence, gallamine binds competitively and with high affinity to NMS-accessible sites on the receptor. Under certain experimental conditions, it also appears to identify another low-affinity site, either due to its binding to NMS-inaccessible sites or through its differential ability to alter the binding of ligands to the main binding domain on the receptor in an allosteric fashion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3418516

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Construction of antagonist dose-response curves for estimation of pA2-values by Schild-plot analysis and detection of allosteric interactions.

Authors:  G Pöch; F Brunner; E Kühberger
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

2.  Radioligand binding to muscarinic receptors of bovine aortic endothelial cells.

Authors:  F Brunner; W R Kukovetz
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

3.  Heterotropic cooperativity within and between protomers of an oligomeric M(2) muscarinic receptor.

Authors:  Rabindra V Shivnaraine; Xi-Ping Huang; Margaret Seidenberg; John Ellis; James W Wells
Journal:  Biochemistry       Date:  2012-05-24       Impact factor: 3.162

4.  Effects of aging on the interaction of quinuclidinyl benzilate, N-methylscopolamine, pirenzepine, and gallamine with brain muscarinic receptors.

Authors:  W Surichamorn; O N Kim; N H Lee; W S Lai; E E el-Fakahany
Journal:  Neurochem Res       Date:  1988-12       Impact factor: 3.996

5.  Allosteric modulation of muscarinic acetylcholine receptors.

Authors:  Karen J Gregory; Patrick M Sexton; Arthur Christopoulos
Journal:  Curr Neuropharmacol       Date:  2007-09       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.